Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCA | P06881 | 8/20 | 0.42 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | MC4R | P32245 | 1/20 | 0.38 |
| ▸ | MC5R | P33032 | 1/20 | 0.38 |
| ▸ | MC3R | P41968 | 1/20 | 0.38 |
| ▸ | MC1R | Q01726 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.37 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12713076 | 0.92 | CALCA (0.46) | CALCACYP51A1EPHX2MC4RMC5R | |
| SCHEMBL12713293 | 0.91 | CALCA (0.46) | CALCA | |
| SCHEMBL12737691 | 0.89 | MC4R (0.44) | CYP51A1MC4RMC5RMC3R | |
| SCHEMBL12713097 | 0.89 | CALCA (0.43) | CALCACYP51A1EPHX2MC4RMC5R | |
| SCHEMBL12713089 | 0.88 | CALCA (0.45) | CALCACYP51A1EPHX2MC4RMC5R | |
| SCHEMBL12713110 | 0.88 | CALCA (0.46) | CALCAEPHX2MC4RMC5RMC3R | |
| SCHEMBL12713302 | 0.87 | CALCA (0.42) | CALCACYP51A1HTR7EPHX2MC4R | |
| SCHEMBL12713085 | 0.87 | CALCA (0.46) | CALCAEPHX2MC4RMC5RMC3R | |
| SCHEMBL12713270 | 0.86 | HTR7 (0.39) | HTR7MC4RHTR1AADAM17ADAMTS5 | |
| SCHEMBL12713046 | 0.86 | MC4R (0.47) | CALCACYP51A1HTR7EPHX2MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086836-A1 | Substituted Phenylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2011-04-14 | — | — | US | disclosed |
| US-20110086836-A1 | Substituted Phenylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086836-A1 | Substituted Phenylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | MC4R, MC5R, MC3R | CALCA 3805/4885CYP51A1 3066/4885HTR7 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.